Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > GeneSegues and Collaborators at University of Minnesota Publish New Research Showing Targeted Nanocapsule Delivery of Plasmid DNA for Long Term Treatment of Hemophilia in Mice

Abstract:
GeneSegues, Inc., a biopharmaceutical company developing and commercializing novel nanocapsule-based drug delivery technology, announced today a publication in the Journal of Clinical Investigation demonstrating that systemic administration of plasmid DNA in liver-targeted, non-viral nanocapsules resulted in complete and long term phenotypic correction of hemophilia A in a mouse model.

GeneSegues and Collaborators at University of Minnesota Publish New Research Showing Targeted Nanocapsule Delivery of Plasmid DNA for Long Term Treatment of Hemophilia in Mice

Chaska, MN | Posted on June 9th, 2009

The work is the result of collaborative studies between GeneSegues and the laboratory of Clifford Steer, M.D., Professor of Medicine, University of Minnesota, and was supported by grants from the National Heart, Lung, and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, and the Department of Defense.

"Hemophilia A is an X-linked congenital bleeding disorder caused by deficiency of coagulation Factor VIII, affecting more than one-half million males worldwide," said lead author Betsy Kren, Ph.D., Assistant Professor of Medicine, University of Minnesota. "Cell-specific delivery of DNA plasmid to the endogenous production site for Factor VIII, to restore Factor VIII levels for an extended period without the development of anti-Factor VIII antibodies, could contribute significantly to a more effective treatment of hemophilia A. To date, no non-viral approach has been identified that is capable of achieving such results. We believe these findings may represent a major advance in the field of gene therapy, and are very encouraged by the results published today with GeneSegues."

The work described in the publication (Kren et al., Journal of Clinical Investigation,
advance online publication 8 June 2009; doi: 10.1172/JCI34332; available at www.jci.org/articles/view/34332), uses the transgene plasmid ‘Sleeping Beauty', expressing B-domain deleted canine Factor VIII and encapsulated in sub-50 nanometer capsules with a hyaluronan ligand shell targeting specifically to liver sinusoidal endothelial cells, to restore Factor VIII levels in Factor VIII knockout mice. The animals were monitored for clotting time by measuring activated partial thromboplastin times (aPTT) over a period of 50 weeks. Single-dose intravenous delivery of the encapsulated plasmid resulted in improvement of aPTT of the treated mice to levels statistically equivalent to wild-type controls through the 50-week study period, while all untreated controls died before the end of the study. Importantly, results showed that the encapsulated plasmid did not activate anti-Factor VIII antibodies.

"Our collaboration with Drs. Steer and Kren and their colleagues has been very productive, and we are pleased to have the opportunity to work with a leading group of researchers in this area," said co-author Gretchen Unger, Ph.D., President of GeneSegues. "We are very encouraged by the results of this hemophilia work, as well as complementary work with reporter genes showing that specific uptake by different liver cell-types corresponds with the applicable capsule targeting ligand. New approaches to gene therapy using nonviral delivery systems may pave the way for novel disease-modifying medicines for hemophilia as well as other diseases of the liver."

####

About GeneSegues
GeneSegues is a privately-held biopharmaceutical company focused on developing and commercializing novel nanocapsule-based drug delivery technology for DNA and RNA-based therapeutics. The company’s sub-50 nanometer (“s50”) capsule technology is unique in the capability to co-opt nondegradative pathways into the target cell, avoiding intracellular drug degradation that has thus far thwarted commercialization of DNA/RNA-based therapeutics. GeneSegues has expertise in working with all types of nucleic acid-based drugs including plasmids and single and double-strand RNAi, in tissue culture and animal models. The company has established collaborative relationships with larger drug developers, whereby s50 technology is being used to deliver nucleic acid-based therapeutics to a broad range of targets, via systemic as well as topical administration.

For more information, please click here

Contacts:
Gretchen M. Unger
President

952-443-3798

Copyright © GeneSegues

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015

A new technique to make drugs more soluble August 28th, 2015

Nanocatalysts improve processes for the petrochemical industry August 28th, 2015

Nanolab Technologies LEAPS Forward with High-Performance Analysis Services to the World: Nanolab Orders Advanced Local Electrode Atom Probe (LEAP®) Microscope from CAMECA Unit of AMETEK Materials Analysis Division August 27th, 2015

Possible Futures

Sediment dwelling creatures at risk from nanoparticles in common household products August 13th, 2015

Harris & Harris Group Reports Financial Statements as of June 30, 2015, and Announces a Stock Repurchase Program August 10th, 2015

Molecular trick alters rules of attraction for non-magnetic metals August 5th, 2015

Global Carbon Nanotubes Industry 2015: Acute Market Reports August 4th, 2015

Nanomedicine

Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015

A new technique to make drugs more soluble August 28th, 2015

These microscopic fish are 3-D-printed to do more than swim: Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities August 26th, 2015

Glitter from silver lights up Alzheimer's dark secrets August 25th, 2015

Announcements

Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015

A new technique to make drugs more soluble August 28th, 2015

Nanocatalysts improve processes for the petrochemical industry August 28th, 2015

Nanolab Technologies LEAPS Forward with High-Performance Analysis Services to the World: Nanolab Orders Advanced Local Electrode Atom Probe (LEAP®) Microscope from CAMECA Unit of AMETEK Materials Analysis Division August 27th, 2015

Nanobiotechnology

Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015

Nanotechnology that will impact the Security & Defense sectors to be discussed at NanoSD2015 conference August 25th, 2015

Louisiana Tech University researchers discover synthesis of a new nanomaterial: Interdisciplinary team creates biocomposite for first time using physiological conditions August 24th, 2015

How UEA research could help build computers from DNA August 19th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic